Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534807 | 0.88 | FFAR4 (0.49) | PPARDPPARGPPARAPTGDR2FFAR4 | |
| SCHEMBL3533093 | 0.85 | PPARD (0.55) | PPARDPPARGPPARA | |
| SCHEMBL3536524 | 0.85 | PPARD (0.49) | PPARDPPARGPPARAPTGDR2TSHR | |
| SCHEMBL3537092 | 0.80 | PPARD (0.50) | PPARDPPARGPPARA | |
| SCHEMBL6273088 | 0.77 | PPARD (0.41) | PPARDPPARGPPARAPTGDR2RXRA | |
| SCHEMBL3532663 | 0.76 | PPARD (0.60) | PPARDPPARGPPARA | |
| SCHEMBL13114000 | 0.75 | PPARD (0.37) | PPARDPPARGPPARAFFAR4RXRA | |
| SCHEMBL3531677 | 0.75 | PPARD (0.48) | PPARDPPARGPPARA | |
| SCHEMBL3534420 | 0.74 | PPARD (0.49) | PPARDPPARGPPARAPTGDR2RXRA | |
| SCHEMBL3533449 | 0.73 | TDP1 (0.43) | PPARDPPARAPTGDR2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | claimed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | claimed |
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.